Joseph Capper Buys 25,000 Shares of TELA Bio (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) Director Joseph Capper acquired 25,000 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of $1.02 per share, with a total value of $25,500.00. Following the completion of the purchase, the director owned 54,827 shares in the company, valued at $55,923.54. The trade was a 83.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

TELA Bio Price Performance

Shares of NASDAQ TELA opened at $1.29 on Friday. The company has a debt-to-equity ratio of 8.82, a current ratio of 2.99 and a quick ratio of 2.38. The firm has a market capitalization of $58.23 million, a PE ratio of -1.68 and a beta of 1.36. TELA Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.69. The business’s fifty day moving average price is $0.79 and its two-hundred day moving average price is $0.79.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $19.29 million for the quarter, compared to analyst estimates of $20.01 million. TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. On average, research analysts expect that TELA Bio, Inc. will post -0.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TELA Bio in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.20.

Hedge Funds Weigh In On TELA Bio

Several large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new stake in shares of TELA Bio during the second quarter worth $4,420,586. Stonepine Capital Management LLC acquired a new position in shares of TELA Bio in the 2nd quarter valued at $1,996,820. BlackRock Inc. acquired a new position in shares of TELA Bio in the 2nd quarter valued at $281,000. UP Strategic Wealth Investment Advisors LLC purchased a new position in TELA Bio in the 2nd quarter worth about $91,000. Finally, WealthTrust Axiom LLC increased its stake in TELA Bio by 39.1% in the 4th quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after purchasing an additional 90,650 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.